Welcome to our dedicated page for Neogen news (Ticker: NEOG), a resource for investors and traders seeking the latest updates and insights on Neogen stock.
Neogen Corporation (NASDAQ: NEOG) generates a steady flow of news related to food safety, animal safety, and global food security. As a Lansing, Michigan-based manufacturer of diagnostics and related products, Neogen regularly issues updates on its financial performance, segment trends, and strategic actions that affect the Food Safety and Animal Safety markets.
On this page, readers can follow earnings releases where Neogen reports revenue, segment performance, gross margin, and non-GAAP measures such as adjusted EBITDA. These updates often break out results for the Food Safety and Animal Safety segments, discuss core revenue trends versus divestitures and discontinued product lines, and provide commentary on product categories like pathogen detection, indicator testing, culture media, biosecurity, and genomics.
Neogen’s news flow also includes announcements about leadership changes, such as the appointment of a new President and Chief Executive Officer, Chief Financial Officer, and senior commercial and business unit leaders. Board transitions, including director retirements and new director appointments, are disclosed through both press releases and related SEC filings.
Sector-specific items appear in Neogen’s news as well, including collaborations in equine health and vaccine offerings such as BotVax B for botulism Type B in horses. The company also announces participation in investor conferences and the timing of quarterly earnings calls and webcasts.
By reviewing the NEOG news feed on this page, investors and observers can track how Neogen describes its progress in food safety, livestock, and pet health and wellness, as well as its strategic transformation efforts, restructuring actions, and capital allocation decisions over time.
Neogen (NASDAQ: NEOG) has announced its participation in the 2024 Wells Fargo Healthcare Conference in Boston, Massachusetts. The event is scheduled for Thursday, September 5, with David Naemura, Neogen's Chief Financial Officer, set to present at 3:00 PM Eastern Time.
Investors and interested parties can access the webcast and presentation materials through the Events & Presentations section of Neogen's Investor Relations website. This conference provides an opportunity for Neogen to showcase its developments and strategies in the healthcare sector to a wider audience of industry professionals and potential investors.
Neogen (NASDAQ: NEOG) has announced a sponsorship agreement with US Equestrian to enhance equine care solutions. The partnership will focus on developing educational materials about equine botulism, a deadly neuromuscular disease affecting horses. Neogen, known for producing BotVax® B, the only USDA-approved vaccine for botulism Type B in horses, will collaborate with US Equestrian to create resources on prevention techniques and treatment protocols.
The initiative aims to raise awareness about the silent killer that can be found in hay, feed, and soil. US Equestrian members will have access to these free resources in fall 2024, coinciding with vaccination season. This partnership underscores Neogen's 30-year commitment to the equestrian community and aligns with US Equestrian's goal of providing quality resources for horse care.
Neogen (NASDAQ: NEOG) announced its fourth-quarter 2024 results, reporting revenue of $236.8 million, a 2.1% decrease from the prior year. The company reported a net loss of $5.4 million, or $(0.02) per diluted share, compared to net income of $5.6 million in the prior-year period. Adjusted Net Income was $22.4 million, or $0.10 per diluted share.
For the full fiscal year 2024, Neogen reported revenue of $924.2 million, a 12.4% increase from the previous year. The company's Adjusted EBITDA for the fourth quarter was $53.0 million, representing a margin of 22.4%. Neogen's CEO, John Adent, noted progress in integration efforts and improvement in order fulfillment rates, despite soft end-market conditions.
Neogen (NASDAQ: NEOG) has announced it will release its fourth-quarter earnings report on Tuesday, July 30, 2024, before the market opens. A webcast and conference call will follow at 8:00 a.m. Eastern time, where executives will discuss the financial results. Interested parties can access the call by dialing (800) 836-8184 (U.S.) or +1 (646) 357-8785 (international) and requesting the Neogen Fourth Quarter 2024 Earnings Call. The live webcast will be available on Neogen's Investor Relations webpage under the 'Events & Presentations' subheading. A replay of the conference call and webcast will be available shortly after the event via the same Investor Relations webpage or by dialing (888) 660-6345 (U.S.) or +1 (646) 517-4150 (international) and using the entry code 82704.
Neogen announced the launch of its Petrifilm® Automated Feeder on June 27, 2024. This system is designed to enhance the efficiency of high-throughput food safety testing by reducing manual tasks. The feeder automates the loading and counting of Petrifilm Plates, processing up to 300 plates in 33 minutes, a significant improvement from the previous 4-hour manual process. The system integrates seamlessly with existing Petrifilm Plate Reader Advanced equipment and lab workflows, helping labs meet food safety standards more efficiently. Preliminary trials have shown a high return on investment and improved lab productivity.
Neogen (NASDAQ: NEOG) announced that its Molecular Detection System has been selected by the USDA Food Safety and Inspection Service (FSIS) as the primary method for detecting Salmonella and Listeria monocytogenes in meat, poultry, and egg products. The USDA FSIS has trusted Neogen's system for over five years due to its reliability and efficiency. The new contract also includes Listeria spp. and the Neogen Molecular Detection Assay 2 for Salmonella Enteritidis and Salmonella Typhimurium. Neogen's system utilizes LAMP technology for fast and accurate pathogen detection and can conduct up to 96 tests simultaneously across various sample types. This recognition underscores Neogen's commitment to global food security.
Neogen has launched CelluSmart technology through Megazyme for measuring cellulosic ethanol in biofuel production. This innovation improves upon the NREL procedure with a yeast-degrading cocktail, enhancing the production of low-carbon fuels. Cellulosic ethanol can reduce greenhouse gas emissions by 60% compared to petroleum-based fuels, promoting progress toward climate goals. CelluSmart technology can help ethanol producers lower carbon intensity scores, potentially opening new markets such as sustainable aviation fuel. The technology is incorporated into ASTM Method E-3417-24, fulfilling EPA's approval requirements for a method from a voluntary consensus standards body.
Neogen (NASDAQ: NEOG), a leader in food safety solutions, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. This event will take place in Miami, Florida, on June 12, 2024. The company's involvement in such a prestigious event highlights its standing in the healthcare sector and offers an opportunity to present its latest innovations and business strategies to a global audience.
Neogen (NASDAQ: NEOG) announced its participation in the 44th Annual William Blair Growth Stock Conference on June 4, 2024, in Chicago, Illinois. John Adent, the company's President and CEO, will present at 8:00 a.m. Central Time. The presentation materials will be available on Neogen's Investor Relations website on the same day. Investors and interested parties can access the webcast and materials through the Events & Presentations section at neogen.com/investor-relations/events-presentations.
Neogen (NASDAQ: NEOG) will participate in the Bank of America 2024 Health Care Conference in Las Vegas, Nevada, on May 15, 2024.